STAT+: Gilead, Bristol jaw over the superiority of rival CAR-T treatments for blood cancer

Competing, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated additional benefit for patients with B-cell lymphoma at an earlier stage of treatment.

Click to view original post